Marina Biotech, Inc

Marina Biotechs focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The companys next-generation of celecoxib, including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our...

Cardiovascular,oncology,primary care,hypertension,pain,fap,colorectal cancer,total care,ace inhibitor,amlodipine,perindopril,celebrex,and cox-2

Marina biotech, inc operates in the Biotechnology research industry.

Marina biotech, inc's revenue is 11m - 100m

Marina biotech, inc has 11 - 50 employees.